Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of everolimus, letrozole and exemestane for advanced HER2 negative breast cancer (BOLERO 4)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
- receptors for oestrogen or progesterone (is hormone receptor positive)
- low or no amounts of HER2 (
More about this trial
- how well everolimus and letrozole worked for advanced breast cancer
- how well everolimus and exemestane worked as the second treatment
- more about the side effects
Summary of results
The trial team found that everolimus and letrozole helped some women with HER2 negative breast cancer that had spread. And most of the side effects were manageable.
They analysed the results in December 2016. They published them in 2018.
202 women took part. Everyone had everolimus and letrozole to begin with. 50 women went on to have everolimus and exemestane when their cancer got worse.
- a swollen mouth and lips (stomatitis)
- weight loss
- a swollen mouth and lips
- weight loss
- chest infection (pneumonia)
- complication of an infection (septic shock)
How to join a clinical trial
Dr Mark Beresford